PERCEPTIVE INFORMATICS EXPANDS NUCLEAR IMAGING CAPABILITIES FOR CARDIOLOGY TRIALS
Boston, MA, November 17, 2009 — Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials. Perceptive has incorporated into its medical imaging technologies components of Hermes Medical Solutions Nuclear Medicine Software Suite and INVIA’s Corridor4DM, a solution for nuclear cardiac quantification and imaging. The solutions allow Perceptive to better integrate several imaging modalities, including Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Multi Gated Acquisition Scan (MUGA) to enhance electronic processing, review, analysis, reporting, and archiving of medical images for cardiology trials.
The Hermes Medical Solutions Nuclear Medicine Software Suite provides the ability to display and reconstruct raw data sets using both back-projection and iterative methods for quantitative analysis. These solutions allow Perceptive to accept images from any scanner and assemble them into a standardized, consistent format for processing and review. Corridor4DM from INVIA offers quantification, review, and reporting of cardiac perfusion, function, and anatomy in 3-D. The system provides advanced processing algorithms and image display for greater diagnostic accuracy and quality assurance. These enhancements further expand Perceptive’s capabilities for medical imaging-based cardiology trials, which include the use of DigiView, a specialized echocardiography image management and reporting system for cardiac function assessment.
“Perceptive is committed to continually incorporating innovative state-of-the-art technologies into our capabilities to help biopharmaceutical companies further improve the use of medical imaging as a surrogate endpoint, or biomarker. Key goals in expanding our capabilities with this advanced nuclear imaging functionality are to help customers make earlier safety and efficacy assessments and better decisions about their compounds in order to bring new cardiovascular treatments to patients sooner,” said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics.
The incorporation of technologies from Hermes Medical Solutions and INVIA supplements the medical imaging capabilities of Perceptive Informatics by providing solutions tailored for cardiology related trials, including specialized PET, SPECT, and MUGA techniques. The Medical Imaging Group of Perceptive Informatics offers a full range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, neurology, rheumatology, cardiology, and endocrinology. Perceptive’s medical imaging technologies are fully validated and in compliance with regulatory guidelines.
# # #
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has more than 9,130 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 as filed with the SEC on November 6, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.